Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ...

The company said its Board approved a fundraise of up to Rs 4,500 crore and is also evaluating a potential merger of Biocon ...

The biosimilars segment, too, will see fresh launches including Bevacizumab in the US, and Semaglutide filings across developed and emerging markets, including India by calendar 2026.

Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs in its key U.S. and European markets.

Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

Aviations stocks: Shares of Interglobe Aviation Ltd, the parent company of India's largest airline IndiGo, and SpiceJet will ...

The company also reported consolidated revenue of Rs 4,454 crore, reflecting a 15% year-on-year increase on a like-for-like ...

BENGALURU/HYDERABAD May 8 (Reuters) - Indian biopharma firm Biocon's (BION.NS), opens new tab profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar ...

Biocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore.

Today, companies across sectors including Titan Company, L&T, Pidilite Industries, Asian Paints, Britannia Industries, Canara ...

Biocon Biologics secures market access agreements for Yesintek, a biosimilar to Stelara, for treating autoimmune diseases in ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...